Monday, June 27, 2011

SGLT2 / Dapagliflzozin in Type 2 diabetes is the next one to be associated with Bladder cancer

After the recent revelation of association of bladder cancer risk with use of Actos, it is the turn of SGLT-2 class as a whole. Long term clincial trials on dapagliflozin suggests a higher risk of bladder cancer is associated with its use. 9 people in dapgliflozin arm got bladder cancer as compared to one in control arm. Dapagliflozin is awaiting approval by YE 2011.  Diabetes drugs are increasingly getting caught in matters of long term safety and this is making regulators cautious in approving drugs for use in diabetes.